Abstract
Purpose: Recurrent urinary tract infections (rUTIs) represent a significant clinical and public health concern, particularly in women. Although commonly encountered, rUTIs involve complex pathophysiology and resistance patterns that complicate diagnosis and treatment. This review aims to synthesize recent literature on rUTIs with a focus on prevalence, pathophysiology, risk factors, diagnostic frameworks, microbial resistance trends, and current and emerging management strategies.
Methods: A comprehensive literature review was conducted using peer-reviewed sources published within the last 10 years, supplemented by current guidelines. Key topics included intracellular bacterial communities, host and behavioral risk factors, emerging resistance patterns, and novel preventive therapies. Sources were identified from PubMed, Web of Science, and recent clinical guidelines. Emphasis was placed on studies with robust sample sizes, high levels of evidence, and clinical relevance to urology practice.
Results: Women are disproportionately affected by rUTIs, with up to 50% experiencing recurrence within one year. Key pathophysiologic mechanisms include formation of intracellular bacterial communities and biofilms that evade host immunity and antimicrobial therapy. The most common uropathogen is Escherichia coli, including increasingly prevalent extended-spectrum beta-lactamase (ESBL)-producing strains. Identified risk factors include sexual activity, postmenopausal estrogen deficiency, urogenital anatomical abnormalities, and genetic non-secretor status. Diagnostic workup should focus on symptom correlation, urine cultures with susceptibility testing, and selective imaging or cystoscopy only in complicated cases. Management includes antibiotic therapy tailored to culture data and local resistance patterns, as well as non-antibiotic preventive strategies such as vaginal estrogen, probiotics, D-mannose, and methenamine hippurate.
Discussion of Results: The rising incidence of antimicrobial resistance highlights the need for antimicrobial stewardship and expanded adoption of non-antibiotic therapies. Although preventive supplements such as cranberry, probiotics, and D-mannose show promise, the data remain mixed. Immunomodulatory therapies are supported by recent randomized trials but are not yet universally accessible. Risk stratification remains an area in need of standardized clinical tools.
Conclusions: rUTIs are a common and burdensome condition requiring individualized management. Understanding host-pathogen interactions, risk factors, and patterns of microbial resistance is essential. Ongoing investigation into non-antibiotic and immunological therapies may significantly reduce recurrence and antibiotic reliance, thereby improving patient outcomes and mitigating resistance development.